Baxalta Races Full Steam Ahead Into 2016 With Hematology At The Fore
This article was originally published in Scrip
Executive Summary
Baxalta Inc. is "energized and optimistic" for the New Year and expects to continue building up a strong portfolio and research pipeline on the back of a successful first six months as an independent new business.
You may also be interested in...
Shire Snags EU Okay For Von Willebrand Drug Veyvondi
Although noises are still being made in Japan concerning the benefits of Shire's merger with Takeda, the former is going about the business of getting marketing green lights with the latest being for its inherited bleeding disorder treatment Veyvondi in Europe.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.